APP and Cognitive impairment: Indeed, in a mouse model of AD, amyloid precursor protein/presenilin1 (APP/PS1) AD mice, Rg1 treatment significantly decreased NOX2 expression in the hippocampus and cortex of APP/PS1 mice and then ROS production, finally ameliorating cognitive impairments and neuronal damage [142].